Physician profile
Sharon E Hill
NPI 1578701603
$863.17
in general payments reported to CMS, 2019-2025
19 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.53 · 2022: $34.52 · 2023: $39.42 · 2024: $253 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $161.87 | 2023-2025 | |
| Dexcom, INC. | $130.92 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbvie INC. | $94.74 | 2024-2025 | |
| Astellas Pharma US INC | $77.79 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.37 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $47.25 | 2025 | |
| Novo Nordisk INC | $42.52 | 2022-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $37.43 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $36.96 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.79 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.11 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $19.53 | 2021 | |
| Amgen INC. | $16.04 | 2024 | Evenity, Prolia |
| Lilly USA, LLC | $15.98 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $15.34 | 2024 | Shingrix, Arexvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14.25 | 2024 | Closurefast |
| Arcutis Biotherapeutics, INC. | $13.80 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $12.76 | 2022 | |
| Sandoz INC. | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.